Healthplus.ai vs Luminare (2026)
Both aim at infection in hospitalized patients, from different angles. Healthplus.ai's PERISCOPE, CE marked in Europe, predicts which adult surgical patients will develop a postoperative bacterial infection at 7 and 30 days, within an hour of surgery ending, and shows the factors behind each prediction in the EHR. It publishes its results by patient subgroup. Luminare argues that prediction is not the bottleneck and sells sepsis screening and intervention software built around the clinical response. Its screening rests on established SIRS criteria rather than a learned model, though it describes itself as artificial intelligence. Choose PERISCOPE to predict surgical infections early; choose Luminare if your gap is acting on sepsis alerts rather than raising them.
- You want a learned model that predicts infection after surgery.
- Each prediction should show the factors behind it.
- Published results by patient subgroup matter to your committee.
- Your gap is responding to sepsis alerts, not generating them.
- Screening should lead straight into an intervention workflow.
- You are comfortable with established criteria rather than a learned model.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Healthplus.ai and Luminare are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Healthplus.ai | Luminare |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Inpatient Deterioration & Risk Monitoring |
| Founded | Not recorded | 2014 |
| Headquarters | Amsterdam, Netherlands | Houston, Texas, United States |
| Website | healthplus.ai | luminare.io |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Healthplus.ai, based in Amsterdam, sells PERISCOPE, CE marked software that predicts which adult surgical patients will develop a postoperative bacterial infection. Within an hour of the end of surgery it gives each patient a probability of infection within 7 days and within 30 days, shown inside the electronic health record as a risk category with the factors that contributed most.
Source: AI Health Index, September 2026
Luminare sells inpatient sepsis screening and intervention software, and its founding argument is that better prediction is not the problem. The company's position, stated on its own site and argued in a peer reviewed review article co authored by its chief executive, is that the health technology industry has concentrated on speed of detection while outcomes stall because clinical staff frequently fail to act on the alert.
Source: AI Health Index, September 2026
Questions buyers ask
How are Healthplus.ai and Luminare priced and sold?
For Healthplus.ai, the company's own research argues local updating is needed for the models to perform at a new hospital, so the question bears on total cost.
With Luminare, the home page says pricing is "based on a combination of your patient volume as well as your expected ROI", with return on investment typically in two to six months, so a hospital can see what drives the cost before contact. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Healthplus.ai and Luminare cover?
In Healthplus.ai's case, the outcome is postoperative bacterial infection broadly, including surgical site infection, pneumonia and urinary tract infection, rather than surgical site infection alone.
For Luminare, the wider company also sells products unrelated to sepsis screening, including a vaccination management platform, an emergency response system, a syndromic screening tool and a record abstraction product named Leonardo, with public sector customers including state health departments, FEMA and Department of Defense. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do Healthplus.ai and Luminare leave to the clinician?
With Healthplus.ai, the published study states that the tool does not recommend specific actions and leaves decisions to clinical judgment, with each department's clinical leadership setting its own protocol around the categories. The company also says each hospital's model is used only once it meets quality benchmarks at that site, and that performance is continuously monitored.
Luminare requires the nurse's assessment as part of the screen, so the system cannot produce an output that a clinician passively ignores. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.
Healthplus.ai's record was reviewed on this site in September 2026; Luminare's site could not be read at review, so parts of its record rest on earlier reads. Neither publishes a price. PERISCOPE has no FDA clearance, and Luminare's page runs from a 30 to 50 percent sepsis mortality rate to lives saved without citing a study of its own product.
Ask Luminare which study supports its outcome claims, and ask Healthplus.ai which markets its CE mark covers.